Lake Street cuts price targets on Biodesix and Starling Oncology shares
Lake Street lowered its Biodesix target to $30 from $40 and Starling Oncology to $8 from $10, keeping Buy ratings on both. Dow Jones Newswires reported the changes.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Analysts at Lake Street reduced their price target on Biodesix (BDSX) shares to $30 from $40 and kept a Buy rating. For Starling Oncology (STLN), the target was cut to $8 from $10 per share, and its Buy rating also stayed in place.
Dow Jones Newswires reported the changes, citing Benzinga ratings data. The report covers only ratings and price targets and includes no new financial figures for either company.
why it matters
Changes like these reflect one analyst's view and usually affect the stocks individually rather than the broader market. Investors in these companies are more likely to be driven by their own results and news.
tags
instruments
sources
- Biodesix Price Target Cut to $30.00/Share From $40.00 by Lake Street — Dow Jones Newswires, 7 November 2026 at 01:39 UTC
- Starling Oncology Price Target Cut to $8.00/Share From $10.00 by Lake Street — Dow Jones Newswires, 7 November 2026 at 01:36 UTC
- Alpha&Omega Semiconductor Price Target Cut to $40.00/Share From $58.00 by Lake Street — Dow Jones Newswires, 7 November 2026 at 01:42 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗